Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN , NOV. 19, 2025 /PRNEWSWIRE/ -- ALKERMES PLC (NASDAQ: ALKS) ("ALKERMES") AND AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL) ("AVADEL") TODAY ANNOUNCED THAT THE COMPANIES HAVE REACHED AGREEMENT ON THE TERMS OF AN INCREASED RECOMMENDED OFFER UNDER WHICH ALKERMES WILL ACQUIRE AVADEL (THE "ACQUISITION") FOR TOTAL TRANSACTION CONSIDERATION OF UP TO $22.50 PER SHARE, CONSISTING OF $21.00 IN CASH AND ONE (1) NON-TRANSFERABLE CONTINGENT VALUE RIGHT ("CVR") ENTITLING HOLDERS TO A POTENTIAL ADDITIONAL CASH PAYMENT OF$1.50PER SHARE, CONTINGENT UPON FINAL U.S. FOOD AND DRUG ADMINISTRATION ("FDA") LUMRYZ APPROVAL (AS DEFINED IN THE FORM OF CVR AGREEMENT TO BE ENTERED INTO BY ALKERMES AND THE RIGHTS AGENT) FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA IN ADULTS BY THE END OF 2028 (THE "INCREASED OFFER").IN CONNECTION WITH THE INCREASED OFFER, ALKERMES AND AVADEL HAVE ENTERED INTO AN AMENDMENT, DATED NOVEMBER 18, 2025 (THE "AMENDMENT"), TO THE DEFINITIVE TRANSACTION AGREEMENT BETWEEN THE PARTIES (THE "TRANSACTION AGREEMENT" AND, AS AMENDED, THE "AMENDED AGREEMENT") PREVIOUSLY ENTERED INTO AND ANNOUNCED ON OCTOBER 22, 2025 (THE "OCTOBER 2.7 ANNOUNCEMENT").

ALKERMES PLC ANNOUNCES INCREASED OFFER TO ACQUIRE AVADEL PHARMACEUTICALS PLC

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014

AVADEL BOARD OF DIRECTORS DECLARES LUNDBECK PROPOSAL A COMPANY SUPERIOR PROPOSAL

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE IRISH TAKEOVER RULES) AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE IRISH TAKEOVER RULES AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE.

AVADEL RECEIVES UNSOLICITED PROPOSAL FROM LUNDBECK

U.K. DISCLOSURE, NOV. 05, 2025 (GLOBE NEWSWIRE) -- AP9 FORM 8.1(A) & (B) (OPENING POSITION DISCLOSURE) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(A) AND (B) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.KEY INFORMATION (A) FULL NAME OF DISCLOSER: AVADEL PHARMACEUTICALS PLC (B) OWNER OR CONTROLLER OF INTERESTS AND SHORT POSITIONS DISCLOSED, IF DIFFERENT FROM 1(A): THE NAMING OF NOMINEE OR VEHICLE COMPANIES IS INSUFFICIENT.

FORM 8.1(A) & (B) - AVADEL PHARMACEUTICALS PLC

 GENERATED LUMRYZ NET PRODUCT REVENUE OF $77.5 MILLION, A 55% INCREASE COMPARED TO THIRD QUARTER 2024   APPROXIMATELY 3,400 PATIENTS ON LUMRYZ AS OF SEPTEMBER 30, 2025, A 48% INCREASE COMPARED TO SEPTEMBER 30, 2024   ANNOUNCED GLOBAL SETTLEMENT OF ALL LITIGATION WITH JAZZ PHARMACEUTICALS, INC. (JAZZ)   ACQUISITION BY ALKERMES PLC (ALKERMES) EXPECTED TO CLOSE IN FIRST QUARTER 2026  DUBLIN, NOV. 04, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE. PENDING ACQUISITION BY ALKERMES: ON OCTOBER 22, 2025, AVADEL ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH ALKERMES WILL ACQUIRE AVADEL FOR TOTAL TRANSACTION CONSIDERATION OF UP TO $20.00 PER SHARE IN CASH, WHICH VALUES AVADEL AT APPROXIMATELY $2.1 BILLION.

AVADEL PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF AVADEL PHARMACEUTICALS PLC (NASDAQGM: AVDL) TO ALKERMES PLC (NASDAQGS: ALKS). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF AVADEL WILL RECEIVE $18.50 PER SHARE, PLUS A NON-TRANSFERABLE CONTINGENT VALUE RIGHT ENTITLING HOLDERS TO A POTENTIAL ADDITIONAL CASH PAYMENT OF $1.50 PER S.

AVADEL PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF AVADEL PHARMACEUTICALS PLC - AVDL

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES   AUGMENTS REVENUE GROWTH PROFILE AND DIVERSIFIES ALKERMES' COMMERCIAL PORTFOLIO WITH NEW HIGH GROWTH PRODUCT, LUMRYZ(SODIUM OXYBATE)  ACCELERATES ALKERMES' COMMERCIAL ENTRY INTO SLEEP MEDICINE MARKET AND PROVIDES STRONG FOUNDATION FOR POTENTIAL LAUNCH OF ALIXOREXTON  EXPECTED TO BE IMMEDIATELY ACCRETIVE AND ENHANCE PROFITABILITY UPON CLOSING  POSITIONS THE COMBINED ORGANIZATION TO ACCELERATE INNOVATION AND EXPAND ITS LEADERSHIP IN DEVELOPMENT OF TREATMENTS FOR SLEEP DISORDERS AND OTHER NEUROLOGICAL DISORDERS  TRANSACTION VALUED AT $18.50 PER SHARE IN CASH WITH A CVR FOR AN ADDITIONAL $1.50 PER SHARE IN CASH, FOR TOTAL CONSIDERATION OF UP TO $20.00 PER SHARE, OR A TRANSACTION VALUE OF UP TO $2.1 BILLION  ALKERMES TO HOST CONFERENCE CALL AND WEBCAST ON OCT. 22, 2025 AT 8:00 A.M. ET DUBLIN , OCT. 22, 2025 /PRNEWSWIRE/ -- ALKERMES PLC(NASDAQ: ALKS) ("ALKERMES") AND AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL) ("AVADEL") TODAY ANNOUNCED THAT THE COMPANIES HAVE ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH ALKERMES WILL ACQUIRE AVADEL, A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY, FOR TOTAL TRANSACTION CONSIDERATION OF UP TO $20.00 PER SHARE IN CASH, WHICH VALUES AVADEL AT APPROXIMATELY $2.1 BILLION AND REPRESENTS A PREMIUM OF 38% TO THE WEIGHTED AVERAGE TRADING PRICE OF AVADEL OVER THE THREE MONTHS PRIOR TO TODAY'S ANNOUNCEMENT AND A PREMIUM OF 12% TO AVADEL'S CLOSING PRICE ON OCT. 21, 2025 (BEING THE LAST BUSINESS DAY PRIOR TO PUBLICATION OF THIS ANNOUNCEMENT).

ALKERMES PLC ANNOUNCES AGREEMENT TO ACQUIRE AVADEL PHARMACEUTICALS PLC

DUBLIN, OCT. 22, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY ANNOUNCED THE GLOBAL SETTLEMENT OF ALL LITIGATION WITH JAZZ PHARMACEUTICALS INC. (JAZZ).

AVADEL PHARMACEUTICALS AND JAZZ PHARMACEUTICALS REACH GLOBAL SETTLEMENT

DUBLIN, OCT. 13, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF AVADEL'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-STATUTORY OPTIONS TO SEVEN (7) NEW EMPLOYEES TO PURCHASE 161,600 ORDINARY SHARES UNDER AVADEL'S 2021 INDUCEMENT PLAN. THE AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEE'S ACCEPTANCE OF EMPLOYMENT WITH AVADEL IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTIONS HAVE A TEN-YEAR TERM AND VEST OVER FOUR YEARS, WITH 25% VESTING ON THE ONE-YEAR ANNIVERSARY OF EACH NEW EMPLOYEE'S RESPECTIVE START DATE AND 25% VESTING ON THE SECOND, THIRD, AND FOURTH ANNIVERSARY THEREAFTER. THE OPTIONS ARE SUBJECT TO THE TERMS AND CONDITIONS OF AVADEL'S 2021 INDUCEMENT PLAN APPROVED BY THE BOARD OF DIRECTORS IN NOVEMBER 2021 AND THE TERMS AND CONDITIONS OF AWARD AGREEMENTS COVERING THE GRANTS.

AVADEL ANNOUNCES GRANT OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

A MEDIA SNIPPET ACCOMPANYING THIS ANNOUNCEMENT IS AVAILABLE BY CLICKING ON THIS LINK. DUBLIN, SEPT.

Avadel Pharmaceuticals plc

AVDL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Avadel Pharmaceuticals plc

AVDL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AVDL